---
title: "Why Recursion Pharmaceuticals Stock Got Mashed on Monday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/250479864.md"
description: "Recursion Pharmaceuticals' stock fell nearly 3% on Monday, underperforming the S&P 500, following news that rival Biodexa launched a phase 3 trial for its drug eRapa targeting familial adenomatous polyposis (FAP). Biodexa's drug has received Fast Track status from the FDA after successful phase 2 results, putting it ahead of Recursion's REC-4881, which completed a phase 1b/2 study earlier this year. Investors are concerned as Biodexa's progress may overshadow Recursion's efforts in developing FAP treatments."
datetime: "2025-07-28T22:47:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/250479864.md)
  - [en](https://longbridge.com/en/news/250479864.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/250479864.md)
---

# Why Recursion Pharmaceuticals Stock Got Mashed on Monday

Clinical-stage biotech **Recursion Pharmaceuticals**' (RXRX -2.85%) stock took it on the chin in the first trading day of the week. Monday saw investors back out of the company's shares, leaving them with an almost 3% decline at market close. The benchmark **S&P 500** (^GSPC 0.02%) did notably better, ticking up slightly on the day.

## A rival reports a major step forward

This was largely due to news from a rival clincal-stage biotech. Late on Friday, U.K.-based **Biodexa** announced it had launched a phase 3 clinical trial of its eRapa, an investigational drug that targets familial adenomatous polyposis (FAP). This is a rare genetic disease which, when left untreated, typically leads to colorectal cancer.

Image source: Getty Images.

Biodexa has been granted Fast Track status for investigating the drug from the U.S. Food and Drug Administration (FDA). This followed a phase 2 clinical trial in which the drug met its primary endpoints.

The advancement of eRapa puts it ahead of Recursion's REC-4881, which is also aimed at treating FAP. The company completed a phase 1b/2 study of the drug earlier this year. Like Biodexa's drug, REC-4881 did well in that stage of testing.

## The best should win

As any seasoned biotech investor would attest, it's the final results and approval process of a drug that ultimately count. Given that, it's hardly encouraging that Biodexa has taken a big step forward ahead of Recursion in the development of its FAP medication. The latter company's investors will be hoping that REC-4881 ultimately proves to be the more efficacious drug for the disorder.

### Related Stocks

- [RXRX.US](https://longbridge.com/en/quote/RXRX.US.md)

## Related News & Research

- [Lux Capital lands $1.5 billion for its largest fund ever](https://longbridge.com/en/news/271833261.md)
- [$1000 Invested In KLA 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/282394230.md)
- [Here’s Why The Dogecoin Price Is Under Threat Of Crashing Again](https://longbridge.com/en/news/282386237.md)
- [Citron Calls Applied Optoelectronics' Valuation 'Delusional'](https://longbridge.com/en/news/282372915.md)
- [BUZZ-Scoring giant FICO slumps as VantageScore competition concerns mount](https://longbridge.com/en/news/282369984.md)